Work
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. It was develop…
Read and enrich the people, organizations and context referenced in case files.
Explore the cases that include this wiki entry.
No case files include this entry yet.
Investigate this subjectWe're looking for works and people connected to this item.
AZD1222
Looking for what this connects to.
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. A study in Scotland found that,
We label verified structured information, user opinions, and AI-discovered relationships separately.
Be the first to comment.
